+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hyperopia - Epidemiology Forecast - 2030

  • ID: 5306990
  • Report
  • March 2021
  • Region: Global
  • 100 pages
  • DelveInsight

This ‘Hyperopia (farsightedness)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hyperopia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hyperopia Understanding

Refractive error indicates that the eye shape does not correctly bend light, resulting in a blurred image. Myopia (nearsightedness), hyperopia (farsightedness), presbyopia (near vision loss with age), and astigmatism are the major forms of refractive errors. Hyperopia, also known as farsightedness, is a refractive defect in which distant objects are usually seen more clearly, but closer objects appear to be blurred. When the eyeball is shorter than normal or has a cornea (clear front window of the eye) that is too flat, hyperopia appears. As a consequence, instead of on it, light rays focus behind the retina. Conventionally, hyperopia is classified into low, moderate, and high to denote the degree of the condition. An error of +2.00 diopters (D) or less is considered low hyperopia. The error between +2.25 and +5.00 D is considered moderate hyperopia, and above this range, it is regarded as high hyperopia. The signs and symptoms of this condition incorporate difficulty with close tasks like reading, eye strain, blurry vision, squinting, and headaches. Symptoms are more prone to manifest with higher degrees of hyperopia. Nonetheless, few patients may encounter all these symptoms, while others may experience some or none, even with a high degree of hyperopia. Hyperopia is believed to be a hereditary condition that runs in families.

Other than genetics, age and underlying medical conditions, such as diabetes, can also contribute to hyperopia development. For the diagnosis purpose, a basic eye test involving a refraction examination and an eye health exam is generally used to detect hyperopia. The doctor looks for clinical signs like visual acuity and performs tests such as corneal examination, pupil examination, slit-lamp examination, retinal examination, and eyelid and conjunctival examination. However, if the diagnosis is delayed or the condition is left untreated in children, complications can arise and may even permanently impair their vision.

Epidemiology Perspective

The Hyperopia epidemiology division provides the insights about historical and current Hyperopia patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2020, the overall prevalent cases of Hyperopia accessed to be around 87,668,351 in the 7MM, which are expected to grow during the forecast period, i.e., 2021-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Hyperopia epidemiology [segmented as Total Prevalent cases of Hyperopia, Total Diagnosed Prevalent cases of Hyperopia, Gender-specific Diagnosed Prevalent Cases of Hyperopia, Age-specific Diagnosed Prevalent Cases of Hyperopia, Severity-Specific Diagnosed Prevalent Cases of Hyperopia and Treated cases of Hyperopia] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2021 to 2030.

Country Wise- Hyperopia Epidemiology

  • In the United States, the total number of prevalent cases of Hyperopia were 16,030,244 in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
  • In the year 2020, the total prevalent cases of Hyperopia were 49,755,755 in EU-5, which are expected to grow during the study period, i.e., 2018-2030.
  • In Japan, the total number of prevalent cases of Hyperopia was 21,882,353 in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
  • In 2020, mild and moderate-to-severe cases of Hyperopia were accounted for 1,522,873 and 13,705,858 in the United States.
  • In the 7MM, the age-specific diagnosed prevalent cases of Hyperopia were 7,713,123, 15,203,292, 18,222,168, 14,995,944, and 12,708,668 for the age-groups 40-49, 50-59, 60-69, 70-79, and ≥80 year, in 2020.

Scope of the Report

  • The Hyperopia report covers a detailed overview explaining its causes, symptoms, and pathophysiology, diagnosis, and treatment patterns.
  • The Hyperopia Report and Model provide an overview of the risk factors and global trends of Hyperopia in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Hyperopia in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Hyperopia.
  • The report provides the segmentation of the Hyperopia epidemiology by total prevalent cases in the 7MM.
  • The report provides the segmentation of the Hyperopia epidemiology by diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the Hyperopia epidemiology by gender-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the Hyperopia epidemiology by age-specific diagnosed prevalent cases in the 7MM.
  • The report provides the segmentation of the Hyperopia epidemiology by severity-specific diagnosed prevalent cases of Hyperopia in the 7MM.
  • The report provides the segmentation of the Hyperopia epidemiology by treated cases of Hyperopia in the 7MM.

Report Highlights

  • 10-Year Forecast of Hyperopia epidemiology
  • 7MM Coverage
  • Epidemiology Segmentation

KOL Views

The publisher interviews, KOL's and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over Hyperopia scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hyperopia?
  • What are the key findings pertaining to the Hyperopia epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018-2030)?
  • What would be the total number of patients of Hyperopia across the 7MM during the study period (2018-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2018-2030)?
  • At what CAGR the patient population is expected to grow in the 7MM during the study period (2018-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Hyperopia?

Reasons to Buy

The Hyperopia Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hyperopia market
  • Quantify patient populations in the global Hyperopia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Hyperopia therapeutics in each of the markets covered
  • Understand the magnitude of Hyperopia population by its severity
  • The Hyperopia epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Hyperopia Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Note: Product cover images may vary from those shown
1. Key Insights

2. Executive Summary of Hyperopia

3. Epidemiology Forecast Flow

4. Disease Background and Overview
4.1. Introduction
4.2. Signs and Symptoms
4.3. Classification
4.4. Causes of Hyperopia
4.5. Clinical types of hyperopia
4.6. Complications
4.7. Pathophysiology
4.8. Diagnosis
4.8.1. Testing

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Assumptions and Rationale
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Prevalent Cases of Hyperopia in the 7MM
5.3.2. Total Diagnosed Prevalent cases of Hyperopia in the 7MM
5.3.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
5.3.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
5.3.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the 7MM
5.3.6. Treated cases of Hyperopia in the 7MM
5.4. The United States
5.4.1. Total Prevalent Cases of Hyperopia in the United States
5.4.2. Total Diagnosed Prevalent cases of Hyperopia in the United States
5.4.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United States
5.4.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the United States
5.4.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United States
5.4.6. Treated cases of Hyperopia in the United States
5.5. EU-5 Epidemiology
5.6. Germany
5.6.1. Total Prevalent Cases of Hyperopia in Germany
5.6.2. Total Diagnosed Prevalent cases of Hyperopia in Germany
5.6.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Germany
5.6.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Germany
5.6.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Germany
5.6.6. Treated cases of Hyperopia in Germany
5.7. France
5.7.1. Total Prevalent Cases of Hyperopia in France
5.7.2. Total Diagnosed Prevalent cases of Hyperopia in France
5.7.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in France
5.7.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in France
5.7.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in France
5.7.6. Treated cases of Hyperopia in France
5.8. Italy
5.8.1. Total Prevalent Cases of Hyperopia in Italy
5.8.2. Total Diagnosed Prevalent cases of Hyperopia in Italy
5.8.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Italy
5.8.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Italy
5.8.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Italy
5.8.6. Treated cases of Hyperopia in Italy
5.9. Spain
5.9.1. Total Prevalent Cases of Hyperopia in Spain
5.9.2. Total Diagnosed Prevalent cases of Hyperopia in Spain
5.9.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Spain
5.9.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Spain
5.9.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Spain
5.9.6. Treated cases of Hyperopia in Spain
5.10. The United Kingdom
5.10.1 . Total Prevalent Cases of Hyperopia in the United Kingdom
5.10.2. Total Diagnosed Prevalent cases of Hyperopia in the United Kingdom
5.10.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
5.10.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
5.10.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom
5.10.6. Treated cases of Hyperopia in the United Kingdom
5.11. Japan Epidemiology
5.11.1. Total Prevalent Cases of Hyperopia in Japan
5.11.2. Total Diagnosed Prevalent cases of Hyperopia in Japan
5.11.3. Gender-specific Diagnosed Prevalent Cases of Hyperopia in Japan
5.11.4. Age-specific Diagnosed Prevalent Cases of Hyperopia in Japan
5.11.5. Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Japan
5.11.6. Treated cases of Hyperopia in Japan

6. Appendix
6.1. Bibliography
6.2. Report Methodology

7. Publisher Capabilities

8. Disclaimer

9. About the Publisher

List of Tables
Table 1 Summary of Hyperopia, Epidemiology, and Key Events (2018-2030)
Table 2 Classification of Hyperopia
Table 3 Total Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Table 4 Total Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Table 5 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Table 6 Age-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Table 7 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Table 8 Treated Cases of Hyperopia in the 7MM (2018-2030)
Table 9 Total Prevalent Cases of Hyperopia in the United States (2018-2030)
Table 10 Total Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Table 11 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Table 12 Age-specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Table 13 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Table 14 Treated Cases of Hyperopia in the United States (2018-2030)
Table 15 Total Prevalent Cases of Hyperopia in Germany (2018-2030)
Table 16 Total Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Table 17 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Table 18 Age-specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Table 19 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Table 20 Treated Cases of Hyperopia in Germany (2018-2030)
Table 21 Total Prevalent Cases of Hyperopia in France (2018-2030)
Table 22 Total Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Table 23 Age-specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Table 24 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Table 25 Treated Cases of Hyperopia in France (2018-2030)
Table 26 Total Prevalent Cases of Hyperopia in Italy (2018-2030)
Table 27 Total Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Table 28 Age-specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Table 29 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Table 30 Treated Cases of Hyperopia in Italy (2018-2030)
Table 31 Total Prevalent Cases of Hyperopia in Spain (2018-2030)
Table 32 Total Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Table 33 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Table 34 Age-specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Table 35 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Table 36 Treated Cases of Hyperopia in Spain (2018-2030)
Table 37 Total Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Table 38 Total Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Table 39 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Table 40 Age-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Table 41 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Table 42 Treated Cases of Hyperopia in the United Kingdom (2018-2030)
Table 43 Total Prevalent Cases of Hyperopia in Japan (2018-2030)
Table 44 Total Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Table 45 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Table 46 Age-specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Table 47 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Table 48 Treated Cases of Hyperopia in Japan (2018-2030)
Table 49 7MM Market Size of Hyperopia in USD Million (2018-2030)
Table 50 7MM Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 51 The United States Market Size of Hyperopia in USD Million (2018-2030)
Table 52 The United States Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 53 Germany Market Size of Hyperopia in USD Million (2018-2030)
Table 54 Germany Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 55 France Market Size of Hyperopia in USD Million (2018-2030)
Table 56 France Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 57 Italy Market Size of Hyperopia in USD Million (2018-2030)
Table 58 Italy Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 59 Spain Market Size of Hyperopia in USD Million (2018-2030)
Table 60 Spain Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 61 The United Kingdom Market Size of Hyperopia in USD Million (2018-2030)
Table 62 The United Kingdom Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Table 63 Japan Market Size of Hyperopia in USD Million (2018-2030)
Table 64 Japan Market Size of Hyperopia by Therapies in USD Million (2018-2030)
Table 65 Price of different surgeries

List of Figures
Figure 1 Normal vs. Hyperopia Vision
Figure 2 Dilated Eye Exam
Figure 3 Visual Acuity Test
Figure 4 Slit-lamp examination
Figure 5 Indirect ophthalmoscopy
Figure 6 LASIK Procedure
Figure 7 LASEK Procedure
Figure 8 LASEK vs. LASIK Procedure
Figure 9 PRK Procedure
Figure 10 PRK Procedure
Figure 11 Total Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Figure 12 Total Diagnosed Prevalent cases of Hyperopia in the 7MM (2018-2030)
Figure 13 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Figure 14 Age-specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Figure 15 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the 7MM (2018-2030)
Figure 16 Treated cases of Hyperopia in the 7MM (2018-2030)
Figure 17 Total Prevalent Cases of Hyperopia in the United States (2018-2030)
Figure 18 Total Diagnosed Prevalent cases of Hyperopia in the United States (2018-2030)
Figure 19 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Figure 20 Age-specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Figure 21 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United States (2018-2030)
Figure 22 Treated cases of Hyperopia in the United States (2018-2030)
Figure 23 Total Prevalent Cases of Hyperopia in Germany (2018-2030)
Figure 24 Total Diagnosed Prevalent cases of Hyperopia in Germany (2018-2030)
Figure 25 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Figure 26 Age-specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Figure 27 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Germany (2018-2030)
Figure 28 Treated cases of Hyperopia in Germany (2018-2030)
Figure 29 Total Prevalent Cases of Hyperopia in France (2018-2030)
Figure 30 Total Diagnosed Prevalent cases of Hyperopia in France (2018-2030)
Figure 31 Gender-specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Figure 32 Gender-specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Figure 33 Age-specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Figure 34 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in France (2018-2030)
Figure 35 Treated cases of Hyperopia in France (2018-2030)
Figure 36 Total Prevalent Cases of Hyperopia in Italy (2018-2030)
Figure 37 Total Diagnosed Prevalent cases of Hyperopia in Italy (2018-2030)
Figure 38 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Figure 39 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Figure 40 Age-specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Figure 41 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Italy (2018-2030)
Figure 42 Treated cases of Hyperopia in Italy (2018-2030)
Figure 43 Total Prevalent Cases of Hyperopia in Spain (2018-2030)
Figure 44 Total Diagnosed Prevalent cases of Hyperopia in Spain (2018-2030)
Figure 45 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Figure 46 Age-specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Figure 47 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Spain (2018-2030)
Figure 48 Treated cases of Hyperopia in Spain (2018-2030)
Figure 49 Total Prevalent Cases of Hyperopia in the United Kingdom(2018-2030)
Figure 50 Total Diagnosed Prevalent cases of Hyperopia in the United Kingdom (2018-2030)
Figure 51 Gender-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Figure 52 Age-specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Figure 53 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Figure 54 Total Prevalent Cases of Hyperopia in the United Kingdom (2018-2030)
Figure 55 Total Prevalent Cases of Hyperopia in Japan (2018-2030)
Figure 56 Total Diagnosed Prevalent cases of Hyperopia in Japan (2018-2030)
Figure 57 Gender-specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Figure 58 Age-specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Figure 59 Severity-Specific Diagnosed Prevalent Cases of Hyperopia in Japan (2018-2030)
Figure 60 Treated cases of Hyperopia in Japan (2018-2030)
Figure 61 Market Size of Hyperopia in the 7MM, USD Million (2018-2030)
Figure 62 7MM Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 63 Market Size of Hyperopia in the United States, USD Million (2018-2030)
Figure 64 The United States Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 65 Market Size of Hyperopia in Germany, USD Million (2018-2030)
Figure 66 Germany Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 67 Market Size of Hyperopia in France, USD Million (2018-2030)
Figure 68 France Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 69 Market Size of Hyperopia in Italy, USD Million (2018-2030)
Figure 70 Italy Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 71 Market Size of Hyperopia in Spain, USD Million (2018-2030)
Figure 72 Spain Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 73 Market Size of Hyperopia in the United KIngdom, USD Million (2018-2030)
Figure 74 The United Kingdom Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Figure 75 Market Size of Hyperopia in Japan, USD Million (2018-2030)
Figure 76 Japan Market Size of Hyperopia by Treatment Options in USD Million (2018-2030)
Note: Product cover images may vary from those shown
Adroll
adroll